Rosuvastatin protects against endothelial cell apoptosis in vitro and alleviates atherosclerosis in ApoE‑/‑ mice by
suppressing endoplasmic reticulum stress

Geng,Jianan; Xu,Huali; Fu,Wenwen; Yu,Xiaofeng; Xu,Guoliang; Cao,Hongyan; Lin,Guangzhu; Sui,Dayun

doi:10.3892/etm.2020.8733

Rosuvastatin protects against endothelial cell apoptosis in vitro and alleviates atherosclerosis in ApoE‑/‑ mice by suppressing endoplasmic reticulum stress

Authors:
- Jianan Geng
- Huali Xu
- Wenwen Fu
- Xiaofeng Yu
- Guoliang Xu
- Hongyan Cao
- Guangzhu Lin
- Dayun Sui
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Cardiovascular Medicine, the Eastern Division of First Hospital, Jilin University, Changchun, Jilin 130031, P.R. China
Published online on: May 8, 2020 https://doi.org/10.3892/etm.2020.8733
Pages: 550-560
Copyright: © Geng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development of abnormal lipid‑induced atherosclerosis is initiated with endothelial cell apoptosis. Vascular endothelial cells possess highly developed endoplasmic reticulum (ER), which is involved in lipid metabolism, indicating that ER stress may contribute chiefly to the induction of endothelial cell apoptosis. Based on its ability to reduce cholesterol levels, rosuvastatin may play an endothelial and vascular protective role by regulating ER stress. In the present study, the involvement of the inhibition of the ER stress‑induced endothelial injury was investigated in combination with the lipid lowering effects of rosuvastatin. This compound can be used to inhibit cholesterol synthesis in atherosclerosis. Rosuvastatin decreased the apoptotic rates of human umbilical vascular endothelial cells (HUVECs) that had been stimulated with ox‑low density lipoprotein (LDL) in vitro and repressed the mRNA levels of CHOP, sXBP1 and caspase‑12, and decreased caspase‑12 activity, as well as the content of glucose‑regulated protein 78 (GRP78), phosphorylated (p)‑protein kinase RNA‑like ER kinase (PERK), p‑inositol‑requiring protein 1α (IRE1α) and p‑eIF2α proteins. In addition, ApoE‑/‑ mice were fed with atherogenic chow for 8 weeks for atherosclerosis induction and rosuvastatin was provided by intragastric administration for an additional 4 weeks. Subsequently, the atherosclerotic plaque formation in the aorta was evaluated by Oil Red O and hematoxylin and eosin staining, and the serum LDL, high‑density lipoprotein, total cholesterol (TC) and triacylglycerol (TG) levels were measured. In addition, the induction of apoptosis of endothelial cells and the expression levels of GRP78, p‑PERK, p‑IRE1α and p‑eIF2α were assessed in the aorta. Rosuvastatin repressed atherosclerotic plaque formation and endothelial apoptosis in the aorta and decreased LDL and TG levels in the serum, as determined by in vivo results. Furthermore, it downregulated the expression levels of protein chaperone GRP78, p‑PERK, p‑IRE1α and p‑eIF2α in the aortic intima. The data indicated that rosuvastatin could protect HUVECs from ER stress‑induced apoptosis triggered by oxidized LDL. It could also inhibit atherosclerosis formation in ApoE‑/‑ mice aorta by regulating the PERK/eIF2α/C/EBPα‑homologous protein and IRE1α/sXBP1 signaling pathways. Taken collectively, the present study demonstrated the preventive and therapeutic effects of rosuvastatin in protecting from the development of endothelial cell dysfunction diseases.

View Figures

View References

1	Hald EM, Lijfering WM, Mathiesen EB, Johnsen SH, Løchen ML, Njølstad I, Wilsgaard T, Rosendaal FR, Brækkan SK and Hansen JB: Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: The Tromso study. Arterioscler Thromb Vasc Biol. 34:226–230. 2014.PubMed/NCBI View Article : Google Scholar
2	Byfield FJ, Tikku S, Rothblat GH, Gooch KJ and Levitan I: OxLDL increases endothelial stiffness, force generation, and network formation. J Lipid Res. 47:715–723. 2006.PubMed/NCBI View Article : Google Scholar
3	Sarvani C, Sireesh D and Ramkumar KM: Unraveling the role of ER stress inhibitors in the context of metabolic diseases. Pharmacol Res. 119:412–421. 2017.PubMed/NCBI View Article : Google Scholar
4	Wu MY, Li CJ, Hou MF and Chu PY: New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 18(2034)2017.PubMed/NCBI View Article : Google Scholar
5	Luchetti F, Crinelli R, Cesarini E, Canonico B, Guidi L, Zerbinati C, Di Sario G, Zamai L, Magnani M, Papa S, et al: Endothelial cells, endoplasmic reticulum stress and oxysterols. Redox Biol. 13:581–587. 2017.PubMed/NCBI View Article : Google Scholar
6	Klausner RD and Sitia R: Protein degradation in the endoplasmic reticulum. Cell. 62:611–614. 1990.PubMed/NCBI View Article : Google Scholar
7	Zhou AX and Tabas I: The UPR in atherosclerosis. Semin Immunopathol. 35:321–332. 2013.PubMed/NCBI View Article : Google Scholar
8	Hong D, Bai YP, Gao HC, Wang X, Li LF, Zhang GG and Hu CP: Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis. 235:310–317. 2014.PubMed/NCBI View Article : Google Scholar
9	Kruzliak P, Sabo J and Zulli A: Endothelial endoplasmic reticulum and nitrative stress in endothelial dysfunction in the atherogenic rabbit model. Acta Histochem. 117:762–766. 2015.PubMed/NCBI View Article : Google Scholar
10	Xu X, Chen Y, Song J, Hou F, Ma X, Liu B and Huang F: Mangiferin suppresses endoplasmic reticulum stress in perivascular adipose tissue and prevents insulin resistance in the endothelium. Eur J Nutr. 57:1563–1575. 2018.PubMed/NCBI View Article : Google Scholar
11	Egom EE, Pharithi RB, Hesse S, Starr N, Armstrong R, Sulaiman HM, Gazdikova K, Mozos I, Caprnda M, Kubatka P, et al: Latest updates on lipid management. High Blood Press Cardiovasc Prev. 26:85–100. 2019.PubMed/NCBI View Article : Google Scholar
12	Breder I, Coope A, Arruda AP, Razolli D, Milanski M, Dorighello GG, de Oliveira HC and Velloso LA: Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosis. Atherosclerosis. 212:30–31. 2010.PubMed/NCBI View Article : Google Scholar
13	Karlson BW, Palmer MK, Nicholls SJ, Lundman P and Barter PJ: A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 117:1444–1448. 2016.PubMed/NCBI View Article : Google Scholar
14	Geng J, Xu H, Yu X, Xu G, Cao H, Lin G and Sui D: Rosuvastatin protects against oxidized low-density lipoprotein-induced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep. 19:432–440. 2019.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Tugcu A, Jin Z, Homma S, Elkind MS, Rundek T, Yoshita M, DeCarli C, Nakanishi K, Shames S, Wright CB, et al: Atherosclerotic plaques in the aortic arch and subclinical cerebrovascular disease. Stroke. 47:2813–2819. 2016.PubMed/NCBI View Article : Google Scholar
17	Li D, Zhang L, Dong F, Liu Y, Li N, Li H, Lei H, Hao F, Wang Y, Zhu Y, et al: Metabonomic changes associated with atherosclerosis progression for LDLR(-/-) mice. J Proteome Res. 14:2237–2254. 2015.PubMed/NCBI View Article : Google Scholar
18	Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A and Nasri H: Atherosclerosis: Process, indicators, risk factors and new hopes. Int J Prev Med. 5:927–946. 2014.PubMed/NCBI
19	Goldstein JL and Brown MS: A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 161:161–172. 2015.PubMed/NCBI View Article : Google Scholar
20	Goyal T, Mitra S, Khaidakov M, Wang X, Singla S, Ding Z, Liu S and Mehta JL: Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep. 14:150–159. 2012.PubMed/NCBI View Article : Google Scholar
21	Zhong X, Ma X, Zhang L, Li Y, Li Y and He R: MIAT promotes proliferation and hinders apoptosis by modulating miR-181b/STAT3 axis in ox-LDL-induced atherosclerosis cell models. Biomed Pharmacother. 97:1078–1085. 2018.PubMed/NCBI View Article : Google Scholar
22	Nègre-Salvayre A, Augé N, Camaré C, Bacchetti T, Ferretti G and Salvayre R: Dual signaling evoked by oxidized LDLs in vascular cells. Free Radic Biol Med. 106:118–133. 2017.PubMed/NCBI View Article : Google Scholar
23	Tao YK, Yu PL, Bai YP, Yan ST, Zhao SP and Zhang GQ: Role of PERK/eIF2α/CHOP endoplasmic reticulum stress pathway in oxidized low-density lipoprotein mediated induction of endothelial apoptosis. Biomed Environ Sci. 29:868–876. 2016.PubMed/NCBI View Article : Google Scholar
24	Sanson M, Augé N, Vindis C, Muller C, Bando Y, Thiers JC, Marachet MA, Zarkovic K, Sawa Y, Salvayre R, et al: Oxidized low-density lipoproteins trigger endoplasmic reticulum stress in vascular cells: Prevention by oxygen-regulated protein 150 expression. Circ Res. 104:328–336. 2009.PubMed/NCBI View Article : Google Scholar
25	Röhrl C and Stangl H: Cholesterol metabolism-physiological regulation and pathophysiological deregulation by the endoplasmic reticulum. Wien Med Wochenschr. 168:280–285. 2018.PubMed/NCBI View Article : Google Scholar
26	Dong Y, Fernandes C, Liu Y, Wu Y, Wu H, Brophy ML, Deng L, Song K, Wen A, Wong S, et al: Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis. Diab Vasc Dis Res. 14:14–23. 2017.PubMed/NCBI View Article : Google Scholar
27	Dickhout JG, Hossain GS, Pozza LM, Zhou J, Lhoták S and Austin RC: Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: Implications in atherogenesis. Arterioscler Thromb Vasc Biol. 25:2623–2629. 2005.PubMed/NCBI View Article : Google Scholar
28	Fu XL and Gao DS: Endoplasmic reticulum proteins quality control and the unfolded protein response: The regulative mechanism of organisms against stress injuries. Biofactors. 40:569–585. 2014.PubMed/NCBI View Article : Google Scholar
29	Lebeau P, Al-Hashimi A, Sood S, Lhoták Š, Yu P, Gyulay G, Paré G, Chen SR, Trigatti B, Prat A, et al: Endoplasmic reticulum stress and Ca2+ depletion differentially modulate the sterol-regulatory protein PCSK9 to control lipid metabolism. J Biol Chem. 292:1510–1523. 2017.PubMed/NCBI View Article : Google Scholar
30	Lenna S, Han R and Trojanowska M: Endoplasmic reticulum stress and endothelial dysfunction. IUBMB Life. 66:530–537. 2014.PubMed/NCBI View Article : Google Scholar
31	Jia F, Wu C, Chen Z and Lu G: Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase. Cardiovasc Ther. 30:317–325. 2012.PubMed/NCBI View Article : Google Scholar
32	Zhao SP, Wu ZH, Wu J, Hong SC and Deng P: Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 46:185–189. 2005.PubMed/NCBI View Article : Google Scholar
33	Chrysant SG: New onset diabetes mellitus induced by statins: Current evidence. Postgrad Med. 129:430–435. 2017.PubMed/NCBI View Article : Google Scholar
34	Raghow R: Statins redux: A re-assessment of how statins lower plasma cholesterol. World J Diabetes. 8:230–234. 2017.PubMed/NCBI View Article : Google Scholar
35	Zhang JY, Liu B, Wang YN, Zhang WN and Wang FJ: Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients. J Mol Neurosci. 52:261–268. 2014.PubMed/NCBI View Article : Google Scholar
36	Adhyaru BB and Jacobson TA: Safety and efficacy of statin therapy. Nat Rev Cardiol. 15:757–769. 2018.PubMed/NCBI View Article : Google Scholar
37	Vargas JI, Arrese M, Shah VH and Arab JP: Use of statins in patients with chronic liver disease and cirrhosis: Current views and prospects. Curr Gastroenterol Rep. 19(43)2017.PubMed/NCBI View Article : Google Scholar
38	Toraldo DM, Benedetto M, Conte L and De Nuccio F: Statins may prevent atherosclerotic disease in OSA patients without co-morbidities? Curr Vasc Pharmacol. 15:5–9. 2017.PubMed/NCBI View Article : Google Scholar